The panel recommends sunitinib, pazopanib, or cabozantinib (consensus; LE: 2b; GR: B) for patients with non-ccRCC after first-line treatment with mTOR inhibitors (Knox et al. 2017; Tannir et al. 2016). The gene discussed is MTOR; the disease is nonpapillary renal cell carcinoma.